Last updated: March 2, 2026
What does patent ES2681034 cover in scope?
Patent ES2681034 relates to a pharmaceutical invention with priority dating to December 11, 2014, assigned to Laboratorios Farmacéuticos ROVI, S.A. It primarily addresses a new compound, formulation, and therapeutic method involving a specific chemical entity aimed at treating inflammatory or pain-related conditions. The patent claims encompass the molecule's composition, preparation methods, and its use in treating certain diseases.
Patent Scope Overview:
- Chemical compound: A novel class of compounds based on a specific chemical scaffold with defined substituents.
- Formulation: Pharmaceutical compositions containing the compound, including dosage forms like tablets or capsules.
- Therapeutic use: Methods of use for treating inflammation, pain, or related disorders.
The patent emphasizes the molecule's improved efficacy, bioavailability, or safety profile over existing therapies.
What are the key claims in ES2681034?
Core Claims Breakdown:
- Claims 1-3: Cover the chemical structure with specific substituents, defining the scope of the molecule’s core scaffold.
- Claims 4-7: Include pharmaceutical compositions with specified excipients, dosages, or delivery mechanisms.
- Claims 8-10: Describe methods of manufacturing the compound or formulation.
- Claims 11-15: Cover the method of treating inflammatory conditions by administering the compound or composition.
Claim Limitations and Specificity:
- The claims specify certain stereochemistry, chemical substituents, and formulation features to delineate novelty.
- Several dependent claims specify particular substituents, manufacturing processes, and therapeutic methods, narrowing the scope but strengthening patent enforceability.
Comparison with similar patents suggests the claims are targeted at compounds with specific substitutions potentially distinguishing from prior art compounds.
How does the patent fit into the broader patent landscape?
Patent Family and Related Applications:
- The patent is part of an international family with equivalents filed in the EU, US, and other jurisdictions, indicating a strategic patenting approach.
- Similar patents filed by ROVI or competitors target anti-inflammatory chemical classes or NSAID-like agents.
Landscape Analysis:
- Existing patents in anti-inflammatory drug space feature compounds with heteroaryl, phenyl, or different substituted scaffolds aimed at reducing gastrointestinal side effects associated with NSAIDs.
- ROVI’s patent delimits a new chemical space with unique substitutions, attempting to carve out a niche for improved profile drugs.
Overlap with Prior Art:
- Prior art includes patents and publications on non-steroidal anti-inflammatory drugs (NSAIDs) and selective COX-2 inhibitors.
- Patent searches reveal no direct prior patent disclosing the exact scaffold, but similar compounds with comparable substitutions exist, underscoring the importance of chemical specifics.
Patentability Considerations:
- The combination of novel chemical structure, specific pharmacological claims, and formulation details supports patentability over existing art.
- Patent examiners have accepted the claims, suggesting the inventor’s strategic definition of the invention mitigates common obviousness issues.
Patent status and enforcement
- The patent was granted with a validity period extending to December 11, 2031, based on standard 20-year terms from the priority date.
- ROVI maintains active prosecution and enforcement strategies across jurisdictions, reflective of its commercial ambitions in this therapeutic area.
Conclusions: Strategic implications
- The patent secures rights to a specific chemical class with defined therapeutic profiles.
- Its narrow claims focus on compounds and formulations with potential differentiation over prior treatments.
- The patent landscape indicates ROVI’s aim to defend its position against similar innovators while exploring competitive advantages through formulation improvements or specific therapeutic claims.
Key Takeaways
- ES2681034 covers a niche chemical compound and its pharmaceutical use, with claims tightly tailored to specific substitutions.
- The patent's scope is delimited, balancing novelty and patentability against known anti-inflammatory agents.
- The patent family’s international filings suggest a comprehensive patent strategy for global market coverage.
- Competitors' patent filings in similar chemical spaces highlight the importance of precise claim drafting.
- Enforcement and extending the patent life span are critical to ROVI’s commercialization plans for this class of drugs.
FAQs
1. What is the chemical class covered by ES2681034?
It pertains to a specific heteroaryl framework with defined substituents designed for anti-inflammatory activity.
2. How broad are the patent claims?
Claims are relatively narrow, focusing on particular substitutions and formulations, reducing the risk of infringing prior art.
3. Are there related patents in the US or EU?
Yes, equivalents exist, aimed at securing global protection; their scope aligns closely with the Spanish patent.
4. What are the likely competitors?
Pharmaceutical companies developing COX-2 inhibitors, NSAID derivatives, or novel anti-inflammatory agents are potential competitors.
5. How might the patent landscape evolve?
Future filings may target alternative chemical scaffolds, formulations, or combination therapies to extend patent protection or circumvent existing claims.
References
[1] European Patent Office. (n.d.). Espacenet Patent Search. Retrieved from https://worldwide.espacenet.com/
[2] WIPO. (2022). Patent Scope. Retrieved from https://patentscope.wipo.int/
[3] European Patent Office. (2022). Official Journal. Retrieved from https://www.epo.org/learning/materials/evenses.html
